The treatment of non-small cell lung cancer (NSCLC) has increasingly shifted toward a personalised approach based on specific genetic alterations. Among these, ROS1 rearrangements define a distinct and clinically important subtype of lung cancer.
Although relatively rare, ROS1-positive lung cancer is highly responsive to targeted therapies. Identifying this alteration allows clinicians to select treatments that directly interfere with the biological mechanisms driving tumour growth.
Topics Covered
Topics Covered
Topics Covered
Topics CoveredWhat Is ROS1-Positive Lung Cancer?
ROS1-positive lung cancer is a subtype of NSCLC caused by a gene fusion involving the ROS1 gene. This fusion leads to the production of an abnormal protein that continuously activates signalling pathways responsible for cell growth and survival.
Unlike point mutations such as KRAS or EGFR, ROS1 alterations are structural rearrangements, meaning part of one gene becomes fused with another.
ROS1 rearrangements occur in approximately:
- 1–2% of non-small cell lung cancers
- most commonly in adenocarcinoma
They are more frequently seen in:
- younger patients
- never-smokers or light smokers
Why ROS1 Rearrangements Matter
Although rare, ROS1-positive lung cancer is particularly important because it is highly targetable.
Targeted therapies for ROS1 have shown:
- significant tumour response rates
- prolonged disease control in many patients
- improved quality of life compared with traditional treatments
This makes accurate identification of ROS1 status a critical step in modern lung cancer care.
How ROS1-Positive Lung Cancer Is Diagnosed
ROS1 rearrangements cannot be identified through imaging alone. Molecular testing is required.
Testing is typically performed on tumour tissue obtained during biopsy. In some cases, liquid biopsy may also detect ROS1 alterations.
Molecular profiling helps identify:
- ROS1 gene fusions
- other actionable alterations such as EGFR, ALK or MET
- biomarkers that guide treatment decisions
Because ROS1-positive lung cancer is uncommon, comprehensive testing is essential to ensure it is not missed.
ROS1-Targeted Therapies
ROS1-positive lung cancer is primarily treated with ROS1 inhibitors, a class of targeted therapies designed to block abnormal signalling caused by the fusion protein.
These therapies:
- inhibit the ROS1 kinase activity
- disrupt tumour growth pathways
- are typically administered orally
Targeted therapy is often used as first-line treatment in metastatic disease, depending on the clinical context.
For many patients, ROS1 inhibitors offer an effective and well-tolerated treatment option.
Treatment Strategy in Metastatic ROS1 Lung Cancer
Management is individualised and usually discussed within a multidisciplinary team (MDT).
Treatment options may include:
- targeted ROS1 therapy
- chemotherapy
- immunotherapy (in selected cases)
- clinical trial participation
Because ROS1-positive cancers often respond well to targeted therapy, treatment decisions focus on maximising response while maintaining quality of life.
Resistance to ROS1-Targeted Therapy
Despite initial effectiveness, resistance to ROS1 inhibitors can develop over time.
This may occur due to:
- secondary mutations affecting drug binding
- activation of alternative signalling pathways
- disease progression in specific sites, such as the brain
When resistance develops, treatment strategies may include:
- switching to next-generation ROS1 inhibitors
- considering combination therapies
- evaluating clinical trial options
Side Effects of ROS1 Inhibitors
ROS1-targeted therapies are generally well tolerated, but side effects can occur.
Common side effects include:
- fatigue
- gastrointestinal symptoms
- dizziness
- liver enzyme changes
Most side effects are manageable with dose adjustments or supportive care.
The Role of Precision Oncology
ROS1-positive lung cancer is a clear example of how precision oncology can transform treatment.
By identifying specific genetic alterations and targeting them directly, clinicians can:
- improve treatment response
- personalise therapy
- reduce unnecessary toxicity
As molecular testing becomes more widespread, identifying rare but actionable alterations such as ROS1 continues to play an essential role in lung cancer care.
Conclusion
ROS1-positive lung cancer represents a rare but highly treatable subtype of non-small cell lung cancer.
Through comprehensive molecular testing and the use of targeted therapies, patients with ROS1 rearrangements can benefit from personalised treatment strategies that improve disease control and contribute to improving lung cancer survival rates.
Support and Follow-Up Care
Dr Papadatos-Pastos and his team provide ongoing support beyond medical treatment.
Patients receive clear communication, psychological care and access to nutrition, physiotherapy and symptom-management services.
Regular follow-up ensures early detection of recurrence and long-term wellbeing.
Book a Consultation
If you or someone close to you has been diagnosed with lung cancer, early consultation with a specialist can make a real difference. Appointments are available at several London clinics.
Faq
Answers to Common Questions
Answers to common questions about ROS1-positive lung cancer, including how ROS1 rearrangements are identified and how targeted therapies are used in modern treatment of non-small cell lung cancer (NSCLC).
ROS1-positive lung cancer is a subtype of NSCLC caused by a gene fusion involving the ROS1 gene.
ROS1 rearrangements occur in approximately 1–2% of non-small cell lung cancer cases.
ROS1 status is identified through molecular testing of tumour tissue or circulating tumour DNA.
ROS1 inhibitors are targeted therapies designed to block abnormal ROS1 signalling.
Yes. Resistance can develop over time, and treatment strategies may need to be adjusted.
